262 related articles for article (PubMed ID: 34597729)
41. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging.
Karmiris K; Bielen D; Vanbeckevoort D; Vermeire S; Coremans G; Rutgeerts P; Van Assche G
Clin Gastroenterol Hepatol; 2011 Feb; 9(2):130-6. PubMed ID: 21056696
[TBL] [Abstract][Full Text] [Related]
42. Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease.
Yang BL; Chen YG; Gu YF; Chen HJ; Sun GD; Zhu P; Shao WJ
World J Gastroenterol; 2015 Feb; 21(8):2475-82. PubMed ID: 25741157
[TBL] [Abstract][Full Text] [Related]
43. Characteristics of Patients with Crohn's Disease With or Without Perianal Fistulae in the CorEvitas Inflammatory Bowel Disease Registry.
Fan Y; Delgado-Aros S; Valdecantos WC; Janak JC; Moore PC; Crabtree MM; Stidham RW
Dig Dis Sci; 2023 Jan; 68(1):214-222. PubMed ID: 35467311
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of the modified Van Assche index for assessing response to anti-TNF therapy with MRI in perianal fistulizing Crohn's disease.
van Rijn KL; Lansdorp CA; Tielbeek JAW; Nio CY; Buskens CJ; D'Haens GRAM; Löwenberg M; Stoker J
Clin Imaging; 2020 Feb; 59(2):179-187. PubMed ID: 31821976
[TBL] [Abstract][Full Text] [Related]
45. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement.
Regueiro M; Mardini H
Inflamm Bowel Dis; 2003 Mar; 9(2):98-103. PubMed ID: 12769443
[TBL] [Abstract][Full Text] [Related]
46. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study.
West RL; van der Woude CJ; Hansen BE; Felt-Bersma RJ; van Tilburg AJ; Drapers JA; Kuipers EJ
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1329-36. PubMed ID: 15606395
[TBL] [Abstract][Full Text] [Related]
47. Predictors of long-term outcomes of radiologically defined perianal fistulizing Crohn's disease treated with antitumor necrosis factor-alpha agents based on Parks' classification.
Azzam N; Alharbi O; Almadi M; Aljebreen A; AlAmeel T; Alabbas M; Bahammam S; Bashmail A; Alomar Y; Mosli M
Eur J Gastroenterol Hepatol; 2020 Feb; 32(2):187-192. PubMed ID: 31851087
[TBL] [Abstract][Full Text] [Related]
48. Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease.
Hindryckx P; Jairath V; Zou G; Feagan BG; Sandborn WJ; Stoker J; Khanna R; Stitt L; van Viegen T; Shackelton LM; Taylor SA; Santillan C; Mearadji B; D'Haens G; Richard MP; Panes J; Rimola J
Gastroenterology; 2019 Nov; 157(5):1233-1244.e5. PubMed ID: 31336124
[TBL] [Abstract][Full Text] [Related]
49. Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease.
Garg R; Aggarwal M; Mohammed A; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
Indian J Gastroenterol; 2023 Oct; 42(5):718-723. PubMed ID: 37523059
[TBL] [Abstract][Full Text] [Related]
50. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease.
Van Assche G; Vanbeckevoort D; Bielen D; Coremans G; Aerden I; Noman M; D'Hoore A; Penninckx F; Marchal G; Cornillie F; Rutgeerts P
Am J Gastroenterol; 2003 Feb; 98(2):332-9. PubMed ID: 12591051
[TBL] [Abstract][Full Text] [Related]
51. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
Reinglas J; Gonczi L; Verdon C; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
Dig Dis Sci; 2020 Jul; 65(7):2046-2053. PubMed ID: 31813132
[TBL] [Abstract][Full Text] [Related]
52. Combining Pentoxifylline With Vedolizumab for Crohn's Disease: Results of a Randomised, Placebo-controlled Pilot Study.
Berera S; Ioannou SC; Morillo D; Mantero AMA; Pignac-Kobinger J; Colina N; Santander AM; Fernandez I; Quintero MA; Rodriguez J; Kerman DH; Damas OM; Czul F; Sussman DA; Abreu MT; Deshpande AR
J Crohns Colitis; 2022 Nov; 16(11):1687-1695. PubMed ID: 35642747
[TBL] [Abstract][Full Text] [Related]
53. Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease.
Chan W; Lynch N; Bampton P; Chang J; Chung A; Florin T; Hetzel DJ; Jakobovits S; Moore G; Pavli P; Radford-Smith G; Thin L; Baraty B; Haifer C; Yau Y; Leong RWL
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):735-740. PubMed ID: 29727386
[TBL] [Abstract][Full Text] [Related]
54. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
[TBL] [Abstract][Full Text] [Related]
55. Anti-TNF and fistulizing perianal Crohn's disease: use in clinical practice.
Bourikas LA; Koutroubakis IE
Curr Drug Targets; 2010 Feb; 11(2):187-97. PubMed ID: 19916954
[TBL] [Abstract][Full Text] [Related]
56. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
Bouguen G; Trouilloud I; Siproudhis L; Oussalah A; Bigard MA; Bretagne JF; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
[TBL] [Abstract][Full Text] [Related]
57. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience.
Topstad DR; Panaccione R; Heine JA; Johnson DR; MacLean AR; Buie WD
Dis Colon Rectum; 2003 May; 46(5):577-83. PubMed ID: 12792431
[TBL] [Abstract][Full Text] [Related]
58. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
Coletta M; Paroni M; Alvisi MF; De Luca M; Rulli E; Mazza S; Facciotti F; Lattanzi G; Strati F; Abrignani S; Fantini MC; Vecchi M; Geginat J; Caprioli F
J Crohns Colitis; 2020 Sep; 14(9):1190-1201. PubMed ID: 32100016
[TBL] [Abstract][Full Text] [Related]
59. Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease.
Waljee AK; Liu B; Sauder K; Zhu J; Govani SM; Stidham RW; Higgins PDR
Inflamm Bowel Dis; 2018 May; 24(6):1185-1192. PubMed ID: 29668915
[TBL] [Abstract][Full Text] [Related]
60. Infliximab and surgical treatment of complex anal Crohn's disease.
Duff S; Sagar PM; Rao M; Dolling S; Sprakes M; Hamlin PJ
Colorectal Dis; 2012 Aug; 14(8):972-6. PubMed ID: 21899707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
